title: Generic Penetration of the SSRI Market.
abstract: In this article, we investigate the penetration of generic selective serotonin reuptake inhibitors (SSRIs) in the US market and the implications for patient out-of-pocket expense. The data suggest that generic penetration into the SSRI market has grown from approximately nine percent in 2000, the year that the patent for Prozac((R)) expired, to 72 percent in 2007. For December, 2007, the difference in patient out-of-pocket expense for branded vs. generic agents was, on average, $55.42 for patients paying by cash (i.e., they had no prescription drug insurance) and $22.39 for patients with insurance coverage.
authors.affiliation: Ms. Cascade is Vice President, Strategic Research and Safety, Quintiles Inc., Falls Church, Virginia.
authors.forename: Elisa F
authors.initials: EF
authors.lastname: Cascade
authors.forename: Amir H
authors.initials: AH
authors.lastname: Kalali